US5672683A
(en)
*
|
1989-09-07 |
1997-09-30 |
Alkermes, Inc. |
Transferrin neuropharmaceutical agent fusion protein
|
US5543390A
(en)
|
1990-11-01 |
1996-08-06 |
State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University |
Covalent microparticle-drug conjugates for biological targeting
|
US5827819A
(en)
*
|
1990-11-01 |
1998-10-27 |
Oregon Health Sciences University |
Covalent polar lipid conjugates with neurologically active compounds for targeting
|
AU5135396A
(en)
*
|
1995-02-28 |
1996-09-18 |
Nature Technology Corporation |
Biosynthetic virus vectors for gene therapy
|
WO1997028817A1
(en)
*
|
1996-02-09 |
1997-08-14 |
Cheng Pi Wan |
Receptor ligand-facilitated delivery of biologically active molecules
|
AU6443298A
(en)
|
1997-02-28 |
1998-09-18 |
Nature Technology Corporation |
Self-assembling genes, vectors and uses thereof
|
WO1999000150A2
(en)
*
|
1997-06-27 |
1999-01-07 |
Regents Of The University Of California |
Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor
|
US7008645B2
(en)
*
|
1998-07-14 |
2006-03-07 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Method of inhibiting restenosis using bisphosphonates
|
US7560424B2
(en)
|
2001-04-30 |
2009-07-14 |
Zystor Therapeutics, Inc. |
Targeted therapeutic proteins
|
US7629309B2
(en)
|
2002-05-29 |
2009-12-08 |
Zystor Therapeutics, Inc. |
Targeted therapeutic proteins
|
CA2481020A1
(en)
*
|
2001-09-28 |
2003-04-03 |
Saoirse Corporation |
Localized non-invasive biological modulation system
|
US20030072761A1
(en)
|
2001-10-16 |
2003-04-17 |
Lebowitz Jonathan |
Methods and compositions for targeting proteins across the blood brain barrier
|
US7045543B2
(en)
|
2001-11-05 |
2006-05-16 |
Enzrel Inc. |
Covalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites
|
CA2481334A1
(en)
*
|
2002-04-01 |
2003-10-16 |
Anthony C. Stevens |
Tissue-specific endothelial membrane proteins
|
NZ571508A
(en)
*
|
2002-05-24 |
2010-05-28 |
Schering Corp |
Neutralizing human anti-IGFR antibody
|
US20070065497A1
(en)
*
|
2005-09-20 |
2007-03-22 |
Guilford Frederick T |
Combination and method using EDTA combined with glutathione in the reduced state encapsulated in a liposome to facilitate the method of delivery of the combination as an oral, topical, intraoral or transmucosal, for anti-thrombin effect and for anti-platelet aggregation and measurement of efficacy
|
US20050142141A1
(en)
*
|
2002-11-27 |
2005-06-30 |
Pardridge William M. |
Delivery of enzymes to the brain
|
US7388079B2
(en)
*
|
2002-11-27 |
2008-06-17 |
The Regents Of The University Of California |
Delivery of pharmaceutical agents via the human insulin receptor
|
EP1620564A4
(de)
*
|
2003-04-18 |
2008-03-12 |
Cytovia Inc |
Verfahren zur behandlung von auf apoptoseinduktion reagierenden krankheiten und screening-tests
|
US10517883B2
(en)
|
2003-06-27 |
2019-12-31 |
Zuli Holdings Ltd. |
Method of treating acute myocardial infarction
|
US20060051407A1
(en)
*
|
2003-06-27 |
2006-03-09 |
Yoram Richter |
Method of treating ischemia-reperfusion injury
|
ATE514783T1
(de)
|
2003-11-12 |
2011-07-15 |
Schering Corp |
Plasmidsystem zur expression mehrerer gene
|
PE20050928A1
(es)
*
|
2003-11-21 |
2005-11-08 |
Schering Corp |
Combinaciones terapeuticas de anticuerpo anti-igfr1
|
US20050244400A1
(en)
|
2004-02-10 |
2005-11-03 |
Zystor Therapeutics, Inc. |
Acid alpha-glucosidase and fragments thereof
|
US8349359B2
(en)
*
|
2004-11-07 |
2013-01-08 |
Your Energy Systems, LLC |
Liposomal formulation for oral administration of glutathione (reduced)
|
DE602005025685D1
(de)
*
|
2004-12-03 |
2011-02-10 |
Schering Corp |
Biologische marker zur vorauswahl von patienten für die anti-igf1r-therapie
|
CA2592320C
(en)
|
2004-12-22 |
2015-11-24 |
Neurochem (International) Limited |
Methods and compositions for treating amyloid-related diseases
|
NZ561648A
(en)
*
|
2005-04-15 |
2009-11-27 |
Schering Corp |
Methods and composition of IGF1R inhibitors for treating or preventing cancer
|
WO2006126208A2
(en)
*
|
2005-05-26 |
2006-11-30 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Compositions and methods using same for delivering agents into a target organ protected by a blood barrier
|
US20060286103A1
(en)
*
|
2005-06-15 |
2006-12-21 |
Parag Kolhe |
Stable antibody formulation
|
CN103396485B
(zh)
|
2005-12-15 |
2016-08-10 |
健泰科生物技术公司 |
靶向多聚泛蛋白的方法和组合物
|
SG173385A1
(en)
|
2006-07-14 |
2011-08-29 |
Ac Immune S A Ch |
Humanized antibody against amyloid beta
|
MY165105A
(en)
|
2006-07-14 |
2018-02-28 |
Ac Immune Sa |
Humanized antibody against amyloid beta
|
LT3851447T
(lt)
|
2006-10-12 |
2023-12-27 |
Bellus Health Inc. |
Metodai, junginiai, kompozicijos ir transporteriai, skirti 3- amino-1- propansulfonrūgšties pristatymui
|
US7960139B2
(en)
|
2007-03-23 |
2011-06-14 |
Academia Sinica |
Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
|
JP2010530744A
(ja)
|
2007-06-12 |
2010-09-16 |
エーシー イミューン ソシエテ アノニム |
アミロイドβに対するヒト化抗体
|
CA2690434C
(en)
|
2007-06-12 |
2018-05-22 |
Ac Immune S.A. |
Monoclonal anti beta amyloid antibody
|
US20090047318A1
(en)
*
|
2007-08-16 |
2009-02-19 |
Abbott Cardiovascular Systems Inc. |
Nanoparticle-coated medical devices and formulations for treating vascular disease
|
CN101998863B
(zh)
|
2007-10-05 |
2015-09-16 |
基因技术公司 |
抗淀粉状蛋白β抗体在眼病中的用途
|
AR069501A1
(es)
|
2007-11-30 |
2010-01-27 |
Genentech Inc |
Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
|
CA2723412A1
(en)
|
2008-05-07 |
2009-11-12 |
Zystor Therapeutics, Inc. |
Lysosomal targeting peptides and uses thereof
|
WO2010009271A2
(en)
|
2008-07-15 |
2010-01-21 |
Academia Sinica |
Glycan arrays on ptfe-like aluminum coated glass slides and related methods
|
EP2342356A4
(de)
|
2008-09-29 |
2012-11-21 |
Univ Ben Gurion |
Amyloid-beta-peptidasen und verwendungsverfahren dafür
|
TWI572357B
(zh)
|
2008-10-14 |
2017-03-01 |
建南德克公司 |
免疫球蛋白變異體及其用途
|
WO2010048446A2
(en)
|
2008-10-22 |
2010-04-29 |
Genentech, Inc. |
Modulation of axon degeneration
|
JP6039183B2
(ja)
|
2008-12-23 |
2016-12-07 |
ジェネンテック, インコーポレイテッド |
プロテインaに対する結合が変化した免疫グロブリン変異体
|
WO2011005098A1
(en)
|
2009-07-10 |
2011-01-13 |
Abbott Healthcare Products B.V. |
Peptide ligands for targeting to the blood-brain barrier
|
ES2599076T3
(es)
|
2009-09-02 |
2017-01-31 |
Genentech, Inc. |
Smoothened mutante y métodos de utilización del mismo
|
CN104043126A
(zh)
|
2009-10-22 |
2014-09-17 |
霍夫曼-拉罗奇有限公司 |
轴突变性的调节
|
US11377485B2
(en)
|
2009-12-02 |
2022-07-05 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
US10087236B2
(en)
|
2009-12-02 |
2018-10-02 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
JP5818805B2
(ja)
|
2009-12-11 |
2015-11-18 |
ジェネンテック, インコーポレイテッド |
抗vegf−c抗体及びその使用方法
|
US8901129B2
(en)
|
2009-12-11 |
2014-12-02 |
Genecode As |
Methods of facilitating neural cell survival using GDNF family ligand (GFL) mimetics or RET signaling pathway activators
|
WO2011079185A1
(en)
|
2009-12-23 |
2011-06-30 |
Genentech, Inc. |
Anti-bv8 antibodies and uses thereof
|
WO2011130332A1
(en)
|
2010-04-12 |
2011-10-20 |
Academia Sinica |
Glycan arrays for high throughput screening of viruses
|
DK2568976T3
(en)
|
2010-05-10 |
2016-01-11 |
Academia Sinica |
Zanamivir-phosphonate congener with the anti-influenza activity, and determining the sensitivity oseltamivir in influenza viruses
|
NZ606357A
(en)
|
2010-07-30 |
2015-05-29 |
Genentech Inc |
Safe and functional humanized anti beta-amyloid antibody
|
EP3527220A1
(de)
|
2010-08-12 |
2019-08-21 |
AC Immune S.A. |
Manipulation von impfstoffen
|
WO2012047968A2
(en)
|
2010-10-05 |
2012-04-12 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
US9304138B2
(en)
|
2010-10-07 |
2016-04-05 |
Katholieke Universiteit Leuven |
Pharmaceutical composition
|
TW201223561A
(en)
|
2010-10-26 |
2012-06-16 |
Ac Immune Sa |
Preparation of an antigenic construct
|
WO2012064836A1
(en)
|
2010-11-10 |
2012-05-18 |
Genentech, Inc. |
Methods and compositions for neural disease immunotherapy
|
LT2646470T
(lt)
|
2010-11-30 |
2017-06-12 |
F. Hoffmann-La Roche Ag |
Mažo giminingumo antitransferino receptorių antikūnai ir jų panaudojimas pernešti gydomąjį vienos grandinės antikūną (scfv) per hematoencefalinį barjerą
|
WO2012118376A1
(en)
|
2011-03-01 |
2012-09-07 |
To-Bbb Holding B.V. |
Advanced active liposomal loading of poorly water-soluble substances
|
US8629114B2
(en)
|
2011-06-03 |
2014-01-14 |
Ophidion Inc. |
Compositions and methods for transport across the blood brain barrier
|
US20140161896A1
(en)
*
|
2011-08-04 |
2014-06-12 |
Ramot At Tel-Aviv University Ltd. |
Particles for the treatment of neurodegenerative diseases
|
KR101981351B1
(ko)
|
2011-10-07 |
2019-09-02 |
에이씨 이뮨 에스.에이. |
타우를 인식하는 포스포특이적 항체
|
EP2766028B1
(de)
|
2011-10-14 |
2017-08-16 |
F. Hoffmann-La Roche AG |
Peptidinhibitoren von bace1
|
JP6338530B2
(ja)
|
2011-11-10 |
2018-06-06 |
ジェネンテック, インコーポレイテッド |
アルツハイマー病を治療、診断、および監視するための方法
|
CN104520322B
(zh)
|
2012-04-05 |
2019-11-15 |
Ac免疫有限公司 |
人源化tau抗体
|
US10130714B2
(en)
|
2012-04-14 |
2018-11-20 |
Academia Sinica |
Enhanced anti-influenza agents conjugated with anti-inflammatory activity
|
SG11201407669QA
(en)
|
2012-05-21 |
2014-12-30 |
Genentech Inc |
Methods for improving safety of blood-brain barrier transport
|
CA2871695A1
(en)
|
2012-05-22 |
2013-11-28 |
F. Hoffmann-La Roche Ag |
Substituted dipyridylamines and uses thereof
|
CN104718188B
(zh)
|
2012-05-22 |
2018-08-21 |
基因泰克公司 |
N-取代的苯甲酰胺类及其在治疗疼痛中的用途
|
WO2014008458A2
(en)
|
2012-07-06 |
2014-01-09 |
Genentech, Inc. |
N-substituted benzamides and methods of use thereof
|
US9914956B2
(en)
|
2012-08-18 |
2018-03-13 |
Academia Sinica |
Cell-permeable probes for identification and imaging of sialidases
|
AU2013305827A1
(en)
|
2012-08-21 |
2015-03-05 |
Academia Sinica |
Benzocyclooctyne compounds and uses thereof
|
BR112015006737A2
(pt)
|
2012-09-27 |
2017-07-04 |
Hoffmann La Roche |
compostos de sulfonamida substituídos
|
AU2013204200B2
(en)
|
2012-10-11 |
2016-10-20 |
Brandeis University |
Treatment of amyotrophic lateral sclerosis
|
MX2015009270A
(es)
|
2013-01-18 |
2015-10-30 |
Hoffmann La Roche |
Pirazoles sustituidos en posicion 3 y uso de los mismos como inhibidores de la cinasa cremallera de leucinas dual (dlk).
|
US9993427B2
(en)
|
2013-03-14 |
2018-06-12 |
Biorest Ltd. |
Liposome formulation and manufacture
|
EP2968280A4
(de)
|
2013-03-14 |
2016-08-10 |
Genentech Inc |
Substituierte triazolopyridine und verfahren zur verwendung davon
|
RU2661111C2
(ru)
|
2013-03-15 |
2018-07-11 |
Ац Иммуне С.А. |
Антитела к тау и способы применения
|
RU2015147601A
(ru)
|
2013-05-01 |
2017-06-05 |
Ф. Хоффманн-Ля Рош Аг |
С-связанные гетероциклоалкилзамещенные пиримидины и их применения
|
MX2015015130A
(es)
|
2013-05-01 |
2016-02-18 |
Hoffmann La Roche |
Compuestos de biheteroarilo y usos de los mismos.
|
KR102293064B1
(ko)
|
2013-05-20 |
2021-08-23 |
제넨테크, 인크. |
항-트랜스페린 수용체 항체 및 사용 방법
|
WO2014210397A1
(en)
|
2013-06-26 |
2014-12-31 |
Academia Sinica |
Rm2 antigens and use thereof
|
US9981030B2
(en)
|
2013-06-27 |
2018-05-29 |
Academia Sinica |
Glycan conjugates and use thereof
|
EP3038600B1
(de)
|
2013-08-27 |
2020-06-03 |
Northeastern University |
System zur freisetzung von wirkstoffen in nanopartikelform und verfahren zur behandlung von krebs und neurotraumata
|
AU2014317889B2
(en)
|
2013-09-06 |
2020-03-05 |
Academia Sinica |
Human iNKT cell activation using glycolipids with altered glycosyl groups
|
TWI657076B
(zh)
|
2013-10-11 |
2019-04-21 |
赫孚孟拉羅股份公司 |
經取代磺醯胺化合物
|
MX2016008110A
(es)
|
2013-12-20 |
2016-08-19 |
Hoffmann La Roche |
Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos.
|
WO2015100269A2
(en)
*
|
2013-12-27 |
2015-07-02 |
Double Helix Corporation |
Compositions and methods for providing active telomerase to cells in vivo
|
US10150818B2
(en)
|
2014-01-16 |
2018-12-11 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
WO2016114819A1
(en)
|
2015-01-16 |
2016-07-21 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
US9982041B2
(en)
|
2014-01-16 |
2018-05-29 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
US20170044232A1
(en)
|
2014-02-04 |
2017-02-16 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
TWI797430B
(zh)
|
2014-03-27 |
2023-04-01 |
中央研究院 |
反應性標記化合物及其用途
|
US10118969B2
(en)
|
2014-05-27 |
2018-11-06 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
US11319567B2
(en)
|
2014-05-27 |
2022-05-03 |
Academia Sinica |
Fucosidase from bacteroides and methods using the same
|
US10005847B2
(en)
|
2014-05-27 |
2018-06-26 |
Academia Sinica |
Anti-HER2 glycoantibodies and uses thereof
|
WO2015184004A1
(en)
|
2014-05-27 |
2015-12-03 |
Academia Sinica |
Anti-cd20 glycoantibodies and uses thereof
|
WO2015184001A1
(en)
|
2014-05-28 |
2015-12-03 |
Academia Sinica |
Anti-tnf-alpha glycoantibodies and uses thereof
|
EP3166939B1
(de)
|
2014-07-07 |
2019-06-05 |
Genentech, Inc. |
Therapeutische verbindungen und verfahren zur verwendung davon
|
CA2960712A1
(en)
|
2014-09-08 |
2016-03-17 |
Academia Sinica |
Human inkt cell activation using glycolipids
|
WO2016081640A1
(en)
|
2014-11-19 |
2016-05-26 |
Genentech, Inc. |
Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
|
CA2966964A1
(en)
|
2014-11-19 |
2016-05-26 |
Michal Novak |
Humanized tau antibodies in alzheimer's disease
|
WO2016081643A1
(en)
|
2014-11-19 |
2016-05-26 |
Genentech, Inc. |
Anti-transferrin receptor antibodies and methods of use
|
EP3845565A3
(de)
|
2014-11-19 |
2021-09-08 |
Genentech, Inc. |
Antikörper gegen bace1 und verwendung davon zur immuntherapie bei neuronalen erkrankungen
|
BR112017011234A2
(pt)
|
2014-12-10 |
2018-03-27 |
Genentech Inc |
anticorpos contra receptor da barreira hematoencefálica e métodos de uso
|
US10495645B2
(en)
|
2015-01-16 |
2019-12-03 |
Academia Sinica |
Cancer markers and methods of use thereof
|
US9975965B2
(en)
|
2015-01-16 |
2018-05-22 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
CN107430127B
(zh)
|
2015-01-24 |
2020-08-28 |
中央研究院 |
癌症标记及其使用方法
|
CA2972072A1
(en)
|
2015-01-24 |
2016-07-28 |
Academia Sinica |
Novel glycan conjugates and methods of use thereof
|
JP6942633B2
(ja)
|
2015-01-30 |
2021-09-29 |
アカデミア シニカAcademia Sinica |
抗体の増強された有効性のための普遍的グリコフォームに関する組成物および方法
|
CA2975875A1
(en)
|
2015-02-04 |
2016-08-11 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
WO2016142310A1
(en)
|
2015-03-09 |
2016-09-15 |
F. Hoffmann-La Roche Ag |
Tricyclic dlk inhibitors and uses thereof
|
CN107835805A
(zh)
|
2015-05-22 |
2018-03-23 |
基因泰克公司 |
被取代的苯甲酰胺和其使用方法
|
CR20170562A
(es)
|
2015-06-24 |
2018-02-01 |
Hoffmann La Roche |
Anticuerpos anti-receptor de transferrina con afinidad diseñada.
|
WO2017035271A1
(en)
|
2015-08-27 |
2017-03-02 |
Genentech, Inc. |
Therapeutic compounds and methods of use thereof
|
WO2017041027A1
(en)
|
2015-09-04 |
2017-03-09 |
Obi Pharma, Inc. |
Glycan arrays and method of use
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
CA2997801A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
|
US10899732B2
(en)
|
2015-11-25 |
2021-01-26 |
Genentech, Inc. |
Substituted benzamides useful as sodium channel blockers
|
JP2019509721A
(ja)
|
2016-02-04 |
2019-04-11 |
キュリス,インコーポレイテッド |
突然変異体スムースンド及びその使用方法
|
CN109195996A
(zh)
|
2016-03-08 |
2019-01-11 |
中央研究院 |
N-聚醣及其阵列的模组化合成方法
|
CN109311995A
(zh)
|
2016-03-29 |
2019-02-05 |
台湾浩鼎生技股份有限公司 |
抗体、药物组合物和方法
|
US10980894B2
(en)
|
2016-03-29 |
2021-04-20 |
Obi Pharma, Inc. |
Antibodies, pharmaceutical compositions and methods
|
JP2019513714A
(ja)
|
2016-03-30 |
2019-05-30 |
ジェネンテック, インコーポレイテッド |
置換ベンズアミド及びその使用方法
|
TWI697333B
(zh)
|
2016-04-22 |
2020-07-01 |
台灣浩鼎生技股份有限公司 |
經由Globo系列抗原之免疫活化或免疫調節之癌症免疫療法
|
JP7043483B2
(ja)
|
2016-07-20 |
2022-03-29 |
エフ.ホフマン-ラ ロシュ アーゲー |
二環式プロリン化合物
|
CN109476628B
(zh)
|
2016-07-20 |
2022-01-11 |
豪夫迈·罗氏有限公司 |
作为trpa1调节剂的磺酰基环烷基酰胺化合物
|
CA3032049C
(en)
|
2016-07-27 |
2023-11-07 |
Obi Pharma, Inc. |
Immunogenic/therapeutic glycan compositions and uses thereof
|
CN110062767B
(zh)
|
2016-07-29 |
2023-07-11 |
台湾浩鼎生技股份有限公司 |
人抗体、药物组合物和方法
|
WO2018029288A1
(en)
|
2016-08-12 |
2018-02-15 |
F. Hoffmann-La Roche Ag |
Sulfonyl pyridyl trp inhibitors
|
JP7213549B2
(ja)
|
2016-08-22 |
2023-01-27 |
シーエイチオー ファーマ インコーポレイテッド |
抗体、結合性断片、および使用の方法
|
EP3526219B1
(de)
|
2016-10-17 |
2021-12-15 |
F. Hoffmann-La Roche AG |
Bicyclische pyridonlactame und verfahren zur verwendung davon
|
US11000601B2
(en)
|
2016-11-21 |
2021-05-11 |
Obi Pharma, Inc. |
Conjugated biological molecules, pharmaceutical compositions and methods
|
JP7171567B2
(ja)
|
2016-11-28 |
2022-11-15 |
エフ.ホフマン-ラ ロシュ アーゲー |
一過性受容体電位型チャネル阻害剤としてのオキサジアゾロン類
|
CN110023313B
(zh)
|
2016-12-02 |
2022-10-25 |
豪夫迈·罗氏有限公司 |
二环酰胺化合物及其使用方法
|
US11072607B2
(en)
|
2016-12-16 |
2021-07-27 |
Genentech, Inc. |
Inhibitors of RIP1 kinase and methods of use thereof
|
CN114874209A
(zh)
|
2017-03-07 |
2022-08-09 |
豪夫迈·罗氏有限公司 |
噁二唑瞬时受体电位通道抑制剂
|
WO2018175707A1
(en)
|
2017-03-24 |
2018-09-27 |
Genentech, Inc. |
4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors
|
CN108939089B
(zh)
*
|
2017-05-17 |
2021-11-02 |
复旦大学 |
群体感应多肽及其在制备肿瘤靶向诊治递药系统中的用途
|
CN110997693A
(zh)
|
2017-06-07 |
2020-04-10 |
阿德克斯公司 |
τ聚集抑制剂
|
TWI805595B
(zh)
|
2017-07-14 |
2023-06-21 |
瑞士商赫孚孟拉羅股份公司 |
二環酮化合物及其使用方法
|
EP3668886A2
(de)
|
2017-08-18 |
2020-06-24 |
Adrx, Inc. |
Peptidinhibitoren der tau-aggregation
|
JP7362600B2
(ja)
|
2017-10-11 |
2023-10-17 |
エフ. ホフマン-ラ ロシュ アーゲー |
Rip1キナーゼ阻害剤として使用するための二環式化合物
|
EP3704145A1
(de)
|
2017-10-30 |
2020-09-09 |
F. Hoffmann-La Roche AG |
Verfahren zur in-vivo-erzeugung multispezifischer antikörper aus monospezifischen antikörpern
|
MX2020003451A
(es)
|
2017-10-31 |
2020-08-03 |
Hoffmann La Roche |
Sulfonas y sulfoxidos biciclicos y metodos de uso de los mismos.
|
AU2018374682B2
(en)
|
2017-11-30 |
2021-12-16 |
Hanmi Pharm. Co., Ltd. |
Salts of 4-amino-N-(1-((3-chloro-2-fluorophenyl)amino)-6-methylisoquinolin-5-yl)thieno(3,2-d)pyrimidine-7-carboxamide, and crystalline forms thereof
|
US11344497B1
(en)
|
2017-12-08 |
2022-05-31 |
Quicksilver Scientific, Inc. |
Mitochondrial performance enhancement nanoemulsion
|
US10722465B1
(en)
|
2017-12-08 |
2020-07-28 |
Quicksilber Scientific, Inc. |
Transparent colloidal vitamin supplement
|
WO2019164778A1
(en)
|
2018-02-20 |
2019-08-29 |
Genentech, Inc. |
Process for preparing 1-arylsulfonyl-pyrrolidine-2-carboxamide transient receptor potential channel antagonist compounds and crystalline forms thereof
|
AR114263A1
(es)
|
2018-02-26 |
2020-08-12 |
Genentech Inc |
Compuestos terapéuticos y métodos para utilizarlos
|
US10710994B2
(en)
|
2018-03-19 |
2020-07-14 |
Genentech, Inc. |
Oxadiazole transient receptor potential channel inhibitors
|
CA3095443A1
(en)
|
2018-03-28 |
2019-10-03 |
Axon Neuroscience Se |
Antibody-based methods of detecting and treating alzheimer's disease
|
JP2021519788A
(ja)
|
2018-03-30 |
2021-08-12 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
ナトリウムチャネル阻害剤としての縮合環ヒドロピリド化合物
|
EP3781571B1
(de)
|
2018-04-20 |
2024-01-17 |
F. Hoffmann-La Roche AG |
N-[4-oxo-2,3-dihydro-pyrido[3,2-b][1,4]oxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol-2-carboxamid-derivate und ähnliche verbindungen als rip1 kinase inhibitoren zur behandlung von z.b. reizdarmsyndrom (rds)
|
TW202003490A
(zh)
|
2018-05-22 |
2020-01-16 |
瑞士商赫孚孟拉羅股份公司 |
治療性化合物及其使用方法
|
TW202035444A
(zh)
|
2018-06-27 |
2020-10-01 |
台灣浩鼎生技股份有限公司 |
用於糖蛋白工程的糖苷合成酶變體及其使用方法
|
TW202024023A
(zh)
|
2018-09-03 |
2020-07-01 |
瑞士商赫孚孟拉羅股份公司 |
治療性化合物及其使用方法
|
JP2022514290A
(ja)
|
2018-12-20 |
2022-02-10 |
ジェネンテック, インコーポレイテッド |
改変抗体fcおよび使用方法
|
AR119673A1
(es)
|
2019-01-11 |
2022-01-05 |
Hoffmann La Roche |
Compuestos bicíclicos de cetona y métodos para utilizarlos
|
EP3946269A4
(de)
*
|
2019-03-27 |
2023-05-03 |
University of Georgia Research Foundation, Inc. |
Verfahren zur herstellung gezielter vesikel und so hergestellte zusammensetzungen
|
US11291702B1
(en)
|
2019-04-15 |
2022-04-05 |
Quicksilver Scientific, Inc. |
Liver activation nanoemulsion, solid binding composition, and toxin excretion enhancement method
|
WO2021097110A1
(en)
|
2019-11-13 |
2021-05-20 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
EP4069734A1
(de)
|
2019-12-04 |
2022-10-12 |
AC Immune SA |
Neuartige moleküle zur therapie und diagnose
|
US11787775B2
(en)
|
2020-07-24 |
2023-10-17 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
WO2022034228A1
(en)
|
2020-08-14 |
2022-02-17 |
Ac Immune Sa |
Humanized anti-tdp-43 binding molecules and uses thereof
|
CN116744933A
(zh)
|
2020-10-02 |
2023-09-12 |
基因泰克公司 |
用于制备双杂芳基化合物及其晶型的方法
|
WO2022079297A1
(en)
|
2020-10-16 |
2022-04-21 |
Ac Immune Sa |
Antibodies binding to alpha-synuclein for therapy and diagnosis
|
WO2023028056A1
(en)
|
2021-08-24 |
2023-03-02 |
Genentech, Inc. |
3-amino piperidyl sodium channel inhibitors
|
WO2023028077A1
(en)
|
2021-08-24 |
2023-03-02 |
Genentech, Inc. |
Sodium channel inhibitors and methods of designing same
|
US20230202984A1
(en)
|
2021-11-24 |
2023-06-29 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
TW202340212A
(zh)
|
2021-11-24 |
2023-10-16 |
美商建南德克公司 |
治療性化合物及其使用方法
|
WO2023156549A1
(en)
|
2022-02-16 |
2023-08-24 |
Ac Immune Sa |
Humanized anti-tdp-43 binding molecules and uses thereof
|
WO2023194565A1
(en)
|
2022-04-08 |
2023-10-12 |
Ac Immune Sa |
Anti-tdp-43 binding molecules
|